Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 2
2019 1
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?
Coutzac C, Funk-Debleds P, Cattey-Javouhey A, Desseigne F, Guibert P, Marolleau P, Rochefort P, de la Fouchardière C. Coutzac C, et al. Among authors: rochefort p. Bull Cancer. 2023 May;110(5):552-559. doi: 10.1016/j.bulcan.2022.08.013. Epub 2022 Oct 10. Bull Cancer. 2023. PMID: 36229267 Free article. Review.
Human papillomavirus type 16 antagonizes IRF6 regulation of IL-1β.
Ainouze M, Rochefort P, Parroche P, Roblot G, Tout I, Briat F, Zannetti C, Marotel M, Goutagny N, Auron P, Traverse-Glehen A, Lunel-Potencier A, Golfier F, Masson M, Robitaille A, Tommasino M, Carreira C, Walzer T, Henry T, Zanier K, Trave G, Hasan UA. Ainouze M, et al. Among authors: rochefort p. PLoS Pathog. 2018 Aug 8;14(8):e1007158. doi: 10.1371/journal.ppat.1007158. eCollection 2018 Aug. PLoS Pathog. 2018. PMID: 30089163 Free PMC article.
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.
de la Fouchardière C, Gamradt P, Chabaud S, Raddaz M, Blanc E, Msika O, Treilleux I, Bachy S, Cattey-Javouhey A, Guibert P, Sarabi M, Rochefort P, Funk-Debleds P, Coutzac C, Ray-Coquard I, Peyrat P, Meeus P, Rivoire M, Dupré A, Hennino A. de la Fouchardière C, et al. Among authors: rochefort p. J Pers Med. 2022 Apr 12;12(4):623. doi: 10.3390/jpm12040623. J Pers Med. 2022. PMID: 35455739 Free PMC article.
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program.
Cassier PA, Peyramaure C, Attignon V, Eberst L, Pacaud C, Boyault S, Desseigne F, Sarabi M, Guibert P, Rochefort P, Marques N, Rivoire M, Dupré A, Peyrat P, Terret C, Ray-Coquard I, Coutzac C, Pérol D, Blay JY, Trédan O, de la Fouchardière C. Cassier PA, et al. Among authors: rochefort p. Transl Oncol. 2022 Jan;15(1):101266. doi: 10.1016/j.tranon.2021.101266. Epub 2021 Nov 15. Transl Oncol. 2022. PMID: 34794033 Free PMC article.
[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].
Bonnet C, Beinse G, Cabel L, Cochereau D, Lavaud P, Rochefort P, Tabouret E, Turpin A, Verlingue L, Vicier C, Massard C. Bonnet C, et al. Among authors: rochefort p. Bull Cancer. 2016 Jun;103(6):594-603. doi: 10.1016/j.bulcan.2016.04.001. Epub 2016 May 24. Bull Cancer. 2016. PMID: 27229364 French.
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Varnier R, et al. Among authors: rochefort p. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. Front Oncol. 2021. PMID: 34631593 Free PMC article.
11 results